Johnson & Johnson led the $93m, two-tranche equity portion, which also included GlaxoSmithKline fund Action Potential Venture Capital.
US-based medical device producer CVRx secured $93m in equity funding led by healthcare group Johnson & Johnson’s Johnson & Johnson Innovation – JJDC subsidiary on Tuesday alongside a $20m term loan agreement.
Action Potential Venture Capital, the venture capital fund launched by pharmaceutical firm GlaxoSmithKline in 2013, also took part in the series G round, as did VC firms New Enterprise Associates (NEA), Ysios Capital, Gilde Healthcare Partners and Windham Venture Partners.
The equity portion will comprise $57.7m of funding…
